Table 3.
Summary of imaging performance measures.
| Per-scan accuracy measures | |||
|---|---|---|---|
| Disease “+” | Disease “−” | Predictive valuea | |
| Positiveb | 92 | 30 | PPV = 75.4% (67.8–83.1) |
| Negative | 36 | 1,721 | NPV = 98.0% (97.3–98.6) |
| Sensitivity and Specificity | Sn = 71.8% (64.1–79.7) | Sp = 98.3% (97.7–98.8) | |
| Per-patient accuracy measures | |||
| Positive | 65 | 27b | PPV = 70.7% (61.3–80.0) |
| Negative | 11 | 419 | NPV = 97.4% (95.9–98.9) |
| Sensitivity and Specificity | Sn = 85.5% (77.6–93.4) | Sp = 93.9% (91.7–96.2) | |
Note: 95% CI shown in parentheses for respective values.
Abbreviations: NPV, negative predictive value; PPV, positive predictive value; Sn, sensitivity; Sp, specificity.
aOne patient was censored from the PPV calculation as they were non-compliant with follow-up despite a TTMV-HPV DNA score of >800 and subsequently died.
bIndeterminate results that prompted clinical action via a biopsy between 1 and 60 days later were considered positive scans, whereas indeterminate results that did not prompt clinical action were considered negative.